Krsnaa Diagnost.

Q4 FY25

Krsnaa Diagnost. Q4 FY25 earnings call: Revenue & Margins

Q4 FY25 earnings call: what management guided on revenue, margins and order book.

Price₹562

Market cap₹1.9K Cr

P/E19.2

Updated23 Aug 2026

Read4 min read

The short version

Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels. FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.

From Krsnaa Diagnost.'s Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

Growth momentum expected to resume in FY '26 with aspirations to surpass previous levels.
Radiology and pathology volumes are increasing, with a balanced 50:50 revenue mix.
Younger centers, especially in radiology, projected to mature and contribute significantly from FY '26 onwards.
Retail business (B2C) anticipated to contribute 5-8% of revenue in FY '26, growing from ~3.5% in Q4 FY '25.
Retail touch points are expanding rapidly (nearly 4x growth in 1 year), supporting growth.
Overall revenue growth target is around 16%+ for FY '26, with expectations to outperform the industry.

2 more points management made on revenue & sales performance

Profitability & Margins

FY25 revenue grew 16% YoY to INR 7,172 million; EBITDA rose 34% to INR 1,958 million with a 27% margin; net profit up 37% to INR 776 million with 11% margin.
Management expects growth momentum to continue with aspirations to surpass FY25 levels into FY26 and beyond.
Younger centers and new projects, including Maharashtra City MRI centers, are expected to mature and drive growth.
ROCE and ROE have improved quarter-on-quarter, expected to improve further as business matures.
Retail (B2C) segment is gaining traction; expected to contribute 5-8% of revenue in FY26 and improve margins gradually.
FY26 capex planned around INR 100-150 crores, with practical cash outflows significantly lower due to asset-light models.

2 more points management made on profitability & margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

For FY '26, planned investments are in the range of INR 100 to 150 crores.
Due to adoption of an asset-light model, actual cash outflow is expected to be significantly less than INR 100 crores.
Investments will focus on implementing sizable tenders won at favorable rates.
Capex mainly targets new radiology centers in Madhya Pradesh, Maharashtra, Delhi, and pathology collection centers in Assam and Orissa.
Collection centers require minimal capex, primarily for basic infrastructure like refrigerators and basic test equipment.
Strategic partnerships involve deferred equipment payments with 7% annual interest to support infrastructure.

2 more points management made on capital expenditure plans

Fundraising & Capital Structure

No explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The company has a gross debt of INR 1,655 million and cash and cash equivalents of INR 1,760 million as of March 31, 2025, indicating a healthy liquidity position.
Management highlighted disciplined capital expenditure plans (capex of INR 100-150 crores for FY '26) aligned with an asset-light model, suggesting controlled capital requirements.
There is no direct reference to plans for raising fresh capital via debt or equity in the near future.

2 more points management made on fundraising & capital structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The company continues to win tenders and deepen its presence in Tier 2 and Tier 3 cities.
There is a strong forward visibility supported by the order book and upcoming project pipeline.
Specific details of tenders in the pipeline are not disclosed due to competition intensity.
Various sizable tenders already won are expected to require investments of about INR 100-150 crores in FY '26.

2 more points management made on order book & pipeline

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹173 Cr, net profit ₹43 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Krsnaa Diagnost.'s management said in earlier quarters

Others in Healthcare Services this season

3B Blackbio DX Ltd (Q4 FY25)
UK subsidiary (TRUPCR Europe Limited) revenue FY 2024-25: GBP 1,287,580, a 94% increase over FY 2023-24 GBP 664,059. Key concall takeaways from 3B Blackbio DX…
Apollo Hospitals Enterprise Ltd (Q4 FY25)
. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Shalby (Q4 FY25)
Implant business is in high-growth mode: 4x growth in Indonesia, 35-40% growth in U.S., and 2.5x growth in India reported last year. Key concall takeaways from…
Suraksha Diagno. (Q4 FY25)
Volume of tests conducted has been growing at around 10% year-on-year between FY '24 and FY '25. Key concall takeaways from Suraksha Diagnostic Ltd's Q4 FY25…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Manipal Health

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Krsnaa Diagnost. Q4 FY25 results?

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

For FY '26, planned investments are in the range of INR 100 to 150 crores.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.